Cargando…
The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats
Background: Angiogenesis is an important determinant of the pathophysiology of portal hypertension contributing to the formation of portosystemic collateral vessels and the hyperdynamic splanchnic circulation associated to this syndrome. Somatostatin and its analogues, like octreotide, have been sho...
Autores principales: | Mejias, Marc, Garcia-Pras, Ester, Tiani, Carolina, Bosch, Jaime, Fernandez, Mercedes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918085/ https://www.ncbi.nlm.nih.gov/pubmed/18194463 http://dx.doi.org/10.1111/j.1582-4934.2008.00218.x |
Ejemplares similares
-
Therapeutic siRNA targeting endothelial KDR decreases portosystemic collateralization in portal hypertension
por: Gallego, Javier, et al.
Publicado: (2017) -
Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer.
por: Macaulay, V. M., et al.
Publicado: (1991) -
The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
por: Li, Su-Chen, et al.
Publicado: (2012) -
Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats
por: Gao, Jin-Hang, et al.
Publicado: (2016) -
Correction: Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats
por: Gao, Jin-Hang, et al.
Publicado: (2022)